Solventum Corp (SOLV) Q3 2025 Earnings Call

Concluded Nov 6, 2025

Nov 6, 2025 0 turns

Period: FY2025 Q3
Runtime: —
Sources: 2 artifacts

8-K 10-Q

Executive readout · one minute

Webcast research workspace

Read the call alongside every captured source. 8-K earnings release, 10-Q stay in one workspace.

Portfolio optimization and M&A 27 Q1 results and execution 18 Health Information Systems / RCM and AI coding 15 Separation from 3M and ERP 14 Transform for the Future savings program 12 MedSurg segment performance 9

Management tone

Confident

Net tone +72 · low hedging

Grounding quotes

“We delivered first quarter results ahead of our plan and ahead of expectations. Organic sales growth and EPS both exceeded our plan”
“Q1 is a clear indication that we are well on our way to delivering our 2026 guidance and, importantly, our go-forward LRP objectives.”
“ACERA, although it's early, the performance reinforces our ability to identify, close, and effectively integrate attractive assets in our space.”
“we would expect our growth rate to improve. And we'd also expect our earnings per share to improve because our operating margin is also improving.”

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Revenue $2.10B +0.7% YoY

Diluted EPS $7.22 +931.4% YoY

Gross margin 54.2% -1.8 pp YoY

Net income $1.27B +937.7% YoY

Research materials

Open the source you need; every reader stays inside this workspace.

8-K earnings release Filed Nov 6, 2025 10-Q report Filed Nov 6, 2025

Quarter detail

How the reported period landed and where the business moved.

Revenue · segments

Med Surg Segment$1.21B +2% YoY

Health Information Systems Segment$345.00M +5.8% YoY

Dental Solutions Segment$340.00M +8.6% YoY

Purification and Filtration Segment$128.00M -28.9% YoY

Read transcripts like this one from Claude, ChatGPT or your own code with the earnings call transcript API →